Stock Scorecard
Stock Summary for Myriad Genetics Inc (MYGN) - $15.30 as of 11/20/2024 8:28:35 PM EST
Total Score
9 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for MYGN
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for MYGN
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for MYGN
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for MYGN
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for MYGN (32 out of 90)
Stock Price Rating (Max of 10) | 6 |
Historical Stock Price Rating (Max of 10) | 6 |
Stock Price Trend (Max of 10) | 2 |
Book Value (Max of 10) | 4 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 4 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 6 |
Price to Earnings (Max of 10) | 0 |
Latest News for for MYGN
Financial Details for MYGN
Company Overview |
|
---|---|
Ticker | MYGN |
Company Name | Myriad Genetics Inc |
Country | USA |
Description | Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah. |
Sector Name | LIFE SCIENCES |
Industry Name | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
Most Recent Quarter | 6/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 15.30 |
Price 4 Years Ago | 19.77 |
Last Day Price Updated | 11/20/2024 8:28:35 PM EST |
Last Day Volume | 687,113 |
Average Daily Volume | 906,070 |
52-Week High | 29.30 |
52-Week Low | 14.91 |
Last Price to 52 Week Low | 2.62% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 44.80 |
Sector PE | 40.32 |
5-Year Average PE | 30.66 |
Free Cash Flow Ratio | 13.91 |
Industry Free Cash Flow Ratio | 41.60 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 1.90 |
Total Cash Per Share | 1.10 |
Book Value Per Share Most Recent Quarter | 8.04 |
Price to Book Ratio | 1.90 |
Industry Price to Book Ratio | 9.11 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 1.69 |
Industry Price to Sales Ratio Twelve Trailing Months | 8.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 4 |
Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
Total Shares Outstanding | 91,035,000 |
Market Capitalization | 1,392,835,500 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 3.63% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -135.09% |
Reported EPS 12 Trailing Months | -1.28 |
Reported EPS Past Year | 0.10 |
Reported EPS Prior Year | -0.28 |
Net Income Twelve Trailing Months | -116,000,000 |
Net Income Past Year | -263,300,000 |
Net Income Prior Year | -112,000,000 |
Quarterly Revenue Growth YOY | 11.20% |
5-Year Revenue Growth | -0.64% |
Operating Margin Twelve Trailing Months | -0.08 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 99,900,000 |
Total Cash Past Year | 97,300,000 |
Total Cash Prior Year | 140,900,000 |
Net Cash Position Most Recent Quarter | 61,100,000 |
Net Cash Position Past Year | 58,800,000 |
Long Term Debt Past Year | 38,500,000 |
Long Term Debt Prior Year | 38,500,000 |
Total Debt Most Recent Quarter | 38,800,000 |
Equity to Debt Ratio Past Year | 0.95 |
Equity to Debt Ratio Most Recent Quarter | 0.95 |
Total Stockholder Equity Past Year | 740,500,000 |
Total Stockholder Equity Prior Year | 783,200,000 |
Total Stockholder Equity Most Recent Quarter | 731,700,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -107,300,000 |
Free Cash Flow Per Share Twelve Trailing Months | -1.18 |
Free Cash Flow Past Year | -184,200,000 |
Free Cash Flow Prior Year | -151,600,000 |
Options |
|
Put/Call Ratio | 0.01 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -2.21 |
MACD Signal | -1.93 |
20-Day Bollinger Lower Band | 17.45 |
20-Day Bollinger Middle Band | 24.97 |
20-Day Bollinger Upper Band | 32.50 |
Beta | 1.94 |
RSI | 21.81 |
50-Day SMA | 22.88 |
150-Day SMA | 21.54 |
200-Day SMA | 23.69 |
System |
|
Modified | 11/19/2024 7:39:10 AM EST |